J.Jpn. Surg. Soc.. 79(9): 1105-1109, 1978
Report on the annual meeting
POSTOPERATIVE LONG TERM CHEMOTHERAPY (PLCC) FOR GASTRIC OR ESOPHAGEAL CANCER
|
2nd Dept. of Surgery, Faculty of Medicine, Kyushu University, Fukuoka, Japan Ryunosuke Kumashiro, Nobuaki Kaibara, Teruhisa Nakamura, Kiyoshi Inokuchi |
The 2 year survival rate was 15 per cent in patients who received an intraoperative Mitomycin-C alone, while it increased to 35 per cent in those receiving the anticancer agents for a prolonged period. The postoperative long-term chemotherapy is assumed to be an effective means of improving the therapeutical results of gastric cancer.
Also against advanced esophageal cancer, the postoperative long-term immunochemotherapy (PLCC) was done with anticancer agents and immunostimulators ,BCG. Although in patients with stage III esophageal cancer who did not receive any immunotherapy, one and two year survival rate were 17 per cent and 0 per cent, they were 35 per cent and 11 per cent respectively in the patients received immunochemotherapy (PLCC).
It is highly suggestive that the PLCC is quite effective in prolonging the life of advanced cancer patients.
A new attempt of administration of anticancer agents under transient clamping of the portal vein was applied for advanced gastric cancer, and a good response is now being obtained in the patients with stage III gastric cancer.
To read the PDF file you will need Adobe Reader installed on your computer.